Abstract: Objective:To study the distribution of the nonfermenter (NF) and the change of its resistance in our hospital, and analyze the risk factors, in order to provide a basis for clinical reasonably antibiotics application. Method:The identification of bacteria was done by API, antibiotic susceptibility was tested by K-B method. Result:355 strains of nonfermenter were separated and the detective rate of NF was 26.2%. Pseudomonas aeruginosa, A. baumanii, Stenotrophomonas maltophilia and Burkholderia cepacia accounted for 62.7％, 12.8％, 11.5％ and 5.4％,respectively. The highest distribution of the NF was in the sputum,the second were wound exudate(10.8%) and drainage(5.2%). The infected patients with a variety of basic diseases were 84.2%. The main distribution of ward:Oncology ward was 51.9% and Internal medicine ward was 25.6%. The resistant rate of Pseudomonas aeruginosa to Imipenem, Piperacillin/tazobactam and Cefoperazone/sulbactam was low. The resistant rate of Acinetobacter to Piperacillin/tazobactam, Imipenem, Amikacin, Ceftazidime and Ciprofloxacin was low. The resistant rate of Stenotrophomonas maltophilia to Minocycline, Paediatric Compound Sulfamethoxazole, Levofloxacin, Piperacillin/tazobactam and Cefoperazone/sulbactam was low. The resistant rate of Burkholderia cepacia to Ceftazidime, Paediatric Compound Sulfamethoxazole, Piperacillin/tazobactam and Cefoperazone/sulbactam was low. Conclusion:Nonfermenter clinically isolated rate and drug resistance rate were high, and its distribution was wide. The hospital should enhance the detection of enzyme producing bacteria and multi-drug resistant bacteria. The treatment of Nonfermente infection should choose the sensitive antibiotics, cure the original diseases actively, and avoid all kinds of risk factors. β-lactam/β-lactamase inhibitor compound preparation such as Piperacillin/Sulbactam and Cefoperazone/sulbactam could be used as the preferred option because of their good antibacterial activity in vitro to nonfermenter.